Jazz PharmaceuticalsJAZZ
JAZZ
About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees: 2,800
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
82% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $15.9M
54% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 50
50% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 9 (+3) [Q3]
5% more funds holding
Funds holding: 447 [Q2] → 468 (+21) [Q3]
1.14% more ownership
Funds ownership: 94.71% [Q2] → 95.85% (+1.14%) [Q3]
3% more capital invested
Capital invested by funds: $6.38B [Q2] → $6.59B (+$211M) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 156
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$162
33%
upside
Avg. target
$184
51%
upside
High target
$207
70%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem 58% 1-year accuracy 23 / 40 met price target | 34%upside $163 | Overweight Reiterated | 12 Dec 2024 |
RBC Capital Gregory Renza 31% 1-year accuracy 27 / 87 met price target | 47%upside $179 | Outperform Reiterated | 12 Dec 2024 |
Needham Ami Fadia 46% 1-year accuracy 77 / 166 met price target | 70%upside $207 | Buy Reiterated | 12 Dec 2024 |
HC Wainwright & Co. Oren Livnat 43% 1-year accuracy 20 / 46 met price target | 64%upside $200 | Buy Reiterated | 22 Nov 2024 |
Baird Joel Beatty 52% 1-year accuracy 22 / 42 met price target | 33%upside $162 | Outperform Maintained | 18 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
4 days ago
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Positive
Seeking Alpha
1 week ago
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Positive
Seeking Alpha
1 month ago
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals Announces CEO Succession Plan
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN , Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025.
Neutral
Zacks Investment Research
1 month ago
5 High ROE Stocks to Buy as Volatility Weighs on Markets
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex®) surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers For U.S. media and investors only DUBLIN , Dec. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced nine company-sponsored Epidiolex ® (cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California. Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with Epidiolex.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A treatment option for Biliary Tract Cancers (BTC). Ziihera was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 20, 2024, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
DUBLIN , Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m.
Neutral
PRNewsWire
1 month ago
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from December 10-13 and 13 abstracts at the 66th Annual American Society of Hematology (ASH) Annual Meeting from December 7-10. A trial-in-progress poster presentation at SABCS outlines the trial design of the ongoing Phase 3 EmpowHER-303 trial (NCT06435429), which is evaluating the efficacy and safety of Ziihera® (zanidatamab-hrii) vs trastuzumab with chemotherapy in patients with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan.
Charts implemented using Lightweight Charts™